Frequently Asked Questions
CSV is a documentation-driven approach to software validation that was designed in the late 1990s and requires comprehensive scripted testing and extensive documentation for all systems. CSA is the FDA’s updated framework, finalized in guidance, that replaces documentation volume with risk-based assurance—requiring quality teams to apply critical thinking to identify which software functions genuinely pose risk to patient safety or data integrity, and calibrate testing and documentation proportionally. CSA is not less validation; it is smarter validation directed at real risk rather than checkbox compliance.
Yes. The FDA’s CSA guidance is final and applies to all manufacturers of FDA-regulated products who use software in production or quality system operations. It covers software used in manufacturing, laboratory operations, clinical data management, quality management, and any other GxP context. Organizations that continue to operate under legacy CSV approaches are not violating the final guidance, but they are operating less efficiently than regulators now expect and may face increased scrutiny during inspections.
ISO/IEC 42001:2023 is the world’s first international standard for Artificial Intelligence Management Systems (AIMS). It matters for life sciences because AI systems in GxP environments introduce risks—particularly model drift and lack of explainability—that traditional software validation frameworks were not designed to address. ISO/IEC 42001 provides the governance architecture for managing AI across its full lifecycle: from data governance and model development through deployment, continuous monitoring, retraining, and decommissioning. Regulators are increasingly expecting life sciences organizations to demonstrate this kind of structured AI oversight.
Model drift occurs when an AI system’s outputs change over time—not because the code changed, but because the data the model encounters has shifted from its training distribution. In a GxP environment, this can cause an AI system to systematically misclassify deviations, underweight emerging risk signals, or produce recommendations that diverge from regulatory expectations—all while appearing to function normally. Without continuous monitoring drift, these changes can go undetected until an inspection or adverse event exposes them. ISO/IEC 42001’s continuous performance evaluation requirements are specifically designed to address this risk.
No. iQuality is designed to work in both scenarios. For organizations without an existing QMS—or running on legacy tools—iQuality’s three modules (Document Xcellence, Validation Xcellence, and Quality Xcellence) provide a complete AI-native quality management platform that deploys in weeks. For organizations with an established QMS, CLAiRE AI agents layer on top of existing infrastructure, adding continuous AI-powered intelligence—including 100% audit trail coverage—without requiring replacement or revalidation of current systems.
CLAiRE is Compliance Group’s purpose-built agentic AI platform, operating on an ISO 13485:2016 life sciences ontology. Unlike AI features in legacy QMS platforms—which are typically bolted onto existing architectures to perform specific tasks like document categorization or basic anomaly detection—CLAiRE agents are designed to reason across entire quality data ecosystems. They connect to existing systems, run continuously, and surface insights that point-in-time human review or rule-based alerts cannot identify. Every CLAiRE agent operates under Compliance Group’s ISO/IEC 42001–certified AI Management System, providing governance that regulated environments require.
CLAiRE’s Audit Trail Review (ATR) agent analyzes 100% of audit trail records—continuously or daily—rather than the 2-5% random sample that most organizations review manually on a quarterly basis. It identifies unauthorized record modifications, timestamp anomalies, access pattern irregularities, and systematic data integrity risks, then generates regulator-ready findings reports with citations, event owners, and evidence chains. The result is a shift from reactive, sample-based audit trail review to proactive, continuous data integrity assurance—with documented coverage that can be presented directly to an FDA auditor.
Standard iQuality configurations deploy in weeks rather than the 12-to-18 months typical of legacy enterprise QMS implementations. The exact timeline depends on which modules are being deployed and the complexity of existing systems to be integrated, but organizations can typically go live with their first module within 4 to 8 weeks. CLAiRE AI agents deployed on top of existing QMS infrastructure have similarly short deployment timelines, as they connect to existing systems rather than replacing them.
The mid-market trap refers to the position many growing biotech organizations find themselves in: they have moved beyond spreadsheets and manual processes but cannot justify the $250,000–$800,000 implementation cost and 12-to-18-month timeline of legacy enterprise QMS platforms. The result is a prolonged period of operating on inadequate quality infrastructure—creating audit exposure, team burnout, and competitive disadvantage—while waiting to reach a size that can justify the enterprise‘s investment. AI-native platforms like iQuality were designed to eliminate this trap by providing enterprise-grade compliance capabilities at mid-market price points with week-scale deployment timelines.
Yes. iQuality’s Document Xcellence module is built with 21 CFR Part 11 compliance—FDA’s regulation governing electronic records and electronic signatures—as a foundational requirement, not an add-on feature. This includes compliant e-signatures via iSign, audit trails for all electronic records, and access controls that meet Part 11 requirements. The platform also operates under ISO 27001 (information security) and SOC 2 Type II (operational trust) certifications.
Compliance Group’s executives co-founded the FICSA (FDA-Industry Computer Software Assurance) Team that contributed to the FDA’s final CSA guidance and co-authored the ISPE GAMP 5 Second Edition—the industry standard for your auditor’s reference. The firm holds the only ISO/IEC 42001 certification in life sciences compliance, alongside ISO 27001 and SOC 2 Type II. With 25 years of GxP expertise and more than 60 client organizations across biotech, pharmaceutical, and medical device, Compliance Group brings together the regulatory depth and practical inspection experience required to build AI that is not just capable, but defensible in regulated environments.
The right starting point depends on your organization’s most urgent compliance risk. For organizations without a QMS or running outdated tools, the module that addresses the most immediate pain—document chaos, validation backlog, or reactive quality management—is typically the best entry point. For organizations with established QMS infrastructure facing an upcoming inspection or recent audit trail finding, CLAiRE’s Audit Trail Review agent addresses the highest-urgency risk. Compliance Group’s 45-minute AI Readiness Assessment provides a scored readiness snapshot and specific module recommendation for your organization’s situation, with no commitment required.
Visit iquality.ai →
Speed without shortcuts. Compliance without complexity. Intelligence without compromise.